Showing results (41-50 of 61) with videos related to
Sort By:
Pageof 7
Inhalation Toxicology|June 16, 2006
Lung dosimetry and risk assessment of nanoparticles: evaluating and extending current models in rats and humansE D Kuempel, C L Tran, V Castranova, et al.Biometrics|September 14, 2000
Statistical comparison of axon-scaled neurochemical productionA J Bailer, S Liu, M L Smith, et al.IARC Scientific Publications|January 1, 1993
Time-to-tumour risk assessment for 1,3-butadiene based on exposure of mice to low doses by inhalationD A Dankovic, R J Smith, L T Stayner, et al.Regulatory Toxicology and Pharmacology : RTP|August 15, 2001
A biomathematical model of particle clearance and retention in the lungs of coal miners. II. Evaluation of variability and uncertaintyE D Kuempel, C L Tran, R J Smith, et al.Annals of the New York Academy of Sciences|February 17, 2000
Sources of uncertainty in dose-response modeling of epidemiological data for cancer risk assessmentL Stayner, A J Bailer, R Smith, et al.American Journal of Industrial Medicine|February 1, 1995
Modeling epidemiologic studies of occupational cohorts for the quantitative assessment of carcinogenic hazardsL Stayner, R Smith, A J Bailer, et al.Mathematical Biosciences|September 27, 2012
Estimating infectivity rates and attack windows for two virusesJ Zhang, D A Noe, J Wu, et al.Toxicological Sciences : an Official Journal of the Society of Toxicology|May 16, 2001
Statistical issues in the analysis of low-dose endocrine disruptor dataJ K Haseman, A J Bailer, R L Kodell, et al.Journal of Cardiovascular Pharmacology|July 1, 1988
Hemodynamic effects of a constant intravenous infusion of piroximone in patients with severe congestive heart failureW E Miller, G T Kennedy, S J Ruberg, et al.The American Journal of Cardiology|August 14, 1987
Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metaboliteR A Okerholm, K Y Chan, J F Lang, et al.Pageof 7